Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Edit custom filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1951 1
1953 4
1954 1
1956 3
1957 2
1958 5
1959 4
1960 17
1961 15
1962 24
1963 15
1964 31
1965 26
1966 36
1967 39
1968 46
1969 32
1970 34
1971 47
1972 35
1973 35
1974 70
1975 42
1976 55
1977 58
1978 56
1979 79
1980 87
1981 82
1982 110
1983 121
1984 125
1985 131
1986 123
1987 135
1988 181
1989 185
1990 229
1991 208
1992 233
1993 229
1994 263
1995 257
1996 280
1997 289
1998 280
1999 297
2000 324
2001 328
2002 284
2003 356
2004 351
2005 380
2006 351
2007 353
2008 385
2009 426
2010 436
2011 495
2012 523
2013 519
2014 541
2015 555
2016 531
2017 511
2018 554
2019 567
2020 631
2021 721
2022 730
2023 645
2024 641
2025 714
2026 158

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

16,160 results

Results by year

Filters applied: . Clear all
Page 1
Did you mean hamamoto k[Author] (444 results)?
A mouse circadian proteome atlas.
Otobe Y, Deki-Arima N, Xinyan S, Itabashi K, Kurabayashi N, Nakamura U, Uchida A, Shimazaki R, Yamamoto K, Sakurai T, Fu YH, Ptáček LJ, Hirano A, Doi M, Yoshitane H. Otobe Y, et al. Among authors: yamamoto k. Mol Cell. 2026 Jan 22;86(2):393-406.e3. doi: 10.1016/j.molcel.2025.12.020. Epub 2026 Jan 9. Mol Cell. 2026. PMID: 41519126 Free article.
Deciphering state-dependent immune features from multi-layer omics data at single-cell resolution.
Edahiro R, Sato G, Naito T, Shirai Y, Saiki R, Sonehara K, Tomofuji Y, Yamamoto K, Namba S, Sasa N, Nagao G, Wang QS, Takahashi Y, Hasegawa T, Kishikawa T, Suzuki K, Liu YC, Motooka D, Takuwa A, Tanaka H, Azekawa S; Japan COVID-19 Task Force; Namkoong H, Koike R, Kimura A, Imoto S, Miyano S, Kanai T, Fukunaga K, Uemura M, Morita T, Kato Y, Hirata H, Takeda Y, Doki Y, Eguchi H, Okuzaki D, Sakakibara S, Ogawa S, Kumanogoh A, Okada Y. Edahiro R, et al. Among authors: yamamoto k. Nat Genet. 2025 Aug;57(8):1905-1921. doi: 10.1038/s41588-025-02266-3. Epub 2025 Jul 28. Nat Genet. 2025. PMID: 40721531 Free PMC article.
Declaration for the eradication of morning hypertension.
Kario K, Nishiyama A, Shibata S, Mogi M, Arima H, Kishi T, Ishida M, Furuhashi M, Ichihara A, Katsuya T, Miura K, Miura SI, Node K, Ohishi M, Shibata H, Shimosawa T, Sugawara A, Tamura K, Toyoda K, Yamamoto K; the Promoting Committee for Morning Hypertension Eradication. Kario K, et al. Among authors: yamamoto k. Hypertens Res. 2025 Sep;48(9):2287-2289. doi: 10.1038/s41440-025-02243-7. Epub 2025 Jul 7. Hypertens Res. 2025. PMID: 40619490 No abstract available.
ARID1A mutation drives gastric tumorigenesis via activating type 2 immune dominant microenvironment.
Arai J, Hayakawa Y, Suzuki N, Kinoshita H, Hata M, Kurokawa K, Matsushita Y, Abe S, Oya Y, Tsuboi M, Ihara S, Iwata Y, Murakami K, Shiokawa T, Shiomi C, Uekura C, Yamamoto K, Fujiwara H, Kawamura S, Nakagawa H, Ikenoue T, Tateno H, Ushiku T, Ijichi H, Hirata Y, Kasuga M, Su GH, Wang TC, Fujishiro M. Arai J, et al. Among authors: yamamoto k. iScience. 2025 Jul 15;28(8):113117. doi: 10.1016/j.isci.2025.113117. eCollection 2025 Aug 15. iScience. 2025. PMID: 40761291 Free PMC article.
Close Spatial Interactions between Cancer Cells and Cancer-Associated Fibroblasts Suppress Antitumor Immunity.
Naoi Y, Inukai Y, Izumikawa T, Nagasaki J, Ishino T, Ueda Y, Thu YM, Fujiwara M, Baba T, Makimoto G, Suzawa K, Okada K, Yamamoto KI, Sakaguchi M, Tomida S, Maeda Y, Toyooka S, Ando M, Togashi Y. Naoi Y, et al. Among authors: yamamoto ki. Cancer Immunol Res. 2025 Sep 2;13(9):1471-1484. doi: 10.1158/2326-6066.CIR-24-1144. Cancer Immunol Res. 2025. PMID: 40590673
A cross-population compendium of gene-environment interactions.
Namba S, Sonehara K, Koyanagi YN, Kikuchi T, Ojima T, Edahiro R, Sato G, Yamaji T, Tomofuji Y, Ueda H, Yamamoto K, Ogawa Y, Suzuki K, Kanai A, Higashiue S, Kobayashi S, Yamaguchi H, Nagata Y, Okazaki Y, Matsumoto N, Motomura K, Koga H, Hishida A, Ikezaki H, Hara M, Nagayoshi M, Oze I, Nakano S; BioBank Japan Project; Oda Y, Suzuki Y, Iwasaki M, Sawada N, Matsuo K, Morisaki T, Yamauchi T, Kadowaki T, Matsuda K, Okada Y. Namba S, et al. Among authors: yamamoto k. Nature. 2026 Jan 28. doi: 10.1038/s41586-025-10054-6. Online ahead of print. Nature. 2026. PMID: 41606330
Efficacy and safety of epcoritamab in Japanese patients with relapsed or refractory diffuse large B-cell lymphoma: 3-year follow-up from the EPCORE NHL-3 trial.
Izutsu K, Kumode T, Yuda J, Nagai H, Mishima Y, Suehiro Y, Yamamoto K, Fujisaki T, Ishitsuka K, Ishizawa K, Ikezoe T, Nishikori M, Akahane D, Fujita J, Jafarinasabian P, Soong D, D'Angelo Månsson B, Takahashi A, Favaro E, Fukuhara N. Izutsu K, et al. Among authors: yamamoto k. Int J Clin Oncol. 2025 Aug;30(8):1631-1640. doi: 10.1007/s10147-025-02788-0. Epub 2025 May 28. Int J Clin Oncol. 2025. PMID: 40434509 Free PMC article. Clinical Trial.
The JSH Morning Hypertension Eradication Program Project.
Kario K, Nishiyama A, Shibata S, Mogi M, Arima H, Kishi T, Ishida M, Furuhashi M, Ichihara A, Katsuya T, Miura K, Miura SI, Ohishi M, Shibata H, Shimosawa T, Sugawara A, Tamura K, Toyoda K, Yamamoto K, Hoshide S, Nakagawa N, Tomita H, Tanaka A, Hozawa A, Hatta T, Nomura A, Kabayama M, Rakugi H, Ohya Y, Node K; Promoting Committee of the Eradication of Morning Hypertension. Kario K, et al. Among authors: yamamoto k. Hypertens Res. 2025 Nov;48(11):2771-2780. doi: 10.1038/s41440-025-02330-9. Epub 2025 Aug 26. Hypertens Res. 2025. PMID: 40858749
Characterization of early-onset gastritis during zolbetuximab-containing chemotherapy in CLDN18.2-positive gastric cancer.
Yamamoto K, Owaki Y, Nakayama I, Sakamoto N, Ishizaka M, Kadota T, Okemoto D, Matsubara Y, Miyashita Y, Kobayashi A, Okazaki U, Seguchi K, Hosokai T, Ogura T, Mishima S, Kotani D, Kawazoe A, Hashimoto T, Kuboki Y, Bando H, Kojima T, Yoshino T, Kuwata T, Ishii G, Yano T, Shitara K. Yamamoto K, et al. ESMO Open. 2025 Oct;10(10):105805. doi: 10.1016/j.esmoop.2025.105805. Epub 2025 Sep 30. ESMO Open. 2025. PMID: 41033281 Free PMC article.
16,160 results
You have reached the last available page of results. Please see the User Guide for more information.